Peritoneal Dialysis Prescription and Adequacy Monitoring

Annabelle N. Chua, MD March 3, 2023





Disclosures

No financial disclosures relevant to this talk

Acknowledgment:

Some slides previously borrowed/modified from Dr. Christine Sethna



Overview

- Physiology of the peritoneal membrane
- Clinical factors that impact peritoneal dialysis
 (PD) prescription in the pediatric population
- PD prescription components
- Role of dialysis adequacy to monitor the effectiveness of peritoneal dialysis



Why Peritoneal Dialysis?

Advantages

- Vascular access not required
 - Better for infants/small children
- Improved fluid balance; less antihypertensive medications
- Fewer dietary restrictions
- Relatively safe and simple
- Allows for regular school attendance
- Better growth
- Less travel to dialysis unit

Disadvantages

- Risk of infection (peritonitis, exit site and tunnel infections)
- Hernias
- Labor intensive; increased caregiver burden
 - Risk of non-adherence
- Decreased appetite
- Body image disturbance



Contraindications to PD

ABSOLUTE


- Omphalocele
- Gastroschisis
- Bladder Exstrophy
- Diaphragmatic hernia
- Obliterated peritoneal cavity
- Peritoneal membrane failure

RELATIVE


- Presence of ileostomies and colostomies
- Infants with significant organomegaly
- Impending abdominal surgery
- Lack of appropriate caregiver for home therapy; lack of appropriate home environment
- Impending (<3-6months) living-donor kidney transplantation



PD Prescription



Physiology of Peritoneal Membrane






PD Prescription Components

- Modality CAPD vs APD
- Solution
- Fill volume
- Dwell Time
- Number of Exchanges




Modality – Continuous Ambulatory Peritoneal Dialysis (CAPD)





Modality – Continuous Ambulatory Peritoneal Dialysis (CAPD)



- Provides continuous solute and fluid removal throughout the day and night
- Daytime exchanges ~5 hours
- Nighttime exchange ~9 hours
- Ease of use
- Low cost of equipment
- Often used in developing countries with limited resources available



Modality – Automated Peritoneal Dialysis (APD)



Nightly Intermittent (NIPD)


Tidal (TPD)











PD Rx: Modality

Determinants of Modality Choice

- Financial
- Center preference
- Geography
- Lifestyle
- Peritoneal membrane transport characteristics



PD Rx: Solution

Composition:


- Water
- Osmotic agent
 - Dextrose (1.5%, 2.5%, 4.25%)
 - Icodextrin
 - Amino acids
- Buffer
 - Lactate
 - Bicarbonate



- Electrolytes
 - Sodium 132-134 mEq/L
 - Chloride 96-105 mEq/L
 - Magnesium 0.25-0.5 mEq/L
 - Calcium 2-3.5 mEq/L
 - No potassium
- Additives
 - Heparin
 - Antibiotics



PD Rx: Solution








Solutions


Table 1 Selected peritoneal dialysis solutions currently available in Europe								
Solution (manufacturer)	рН	Chambers	Buffer	Osmotic agent	GDPs	Advantages	Disadvantages	
Dianeal® (Baxter*)	5.2	Single	Lactate	Glucose	High	Easy to manufacture; low cost	Low pH; poor peritoneal membrane biocompatibility; infusion pain; contains lactate	
Extraneal®	5.6	Single	Lactate	Icodextrin	Low	Sustained ultrafiltration; reduced	Contains lactate; low pH; single	
(Baxter*)						Glucose degradation	daily use only; hypersensitivity	
Nutrineal* (Baxter*)	5.5	Single	Lactate	Amino acids	No	products	Contains lactate; low pH; single daily use only	
Physioneal® (Baxter*)	7.4	Double	Lactate/ bicarbonate	Glucose	Low	Improved biocompatibility; preserved membrane defense; reduced infusion pain	Local and systemic glucose exposure; reduced peritoneal lactate exposure	
Stay-safe® (Fresenius‡)	5.5	Demex	Lactate	Glucose	High	Ease of manufacture; low cost	Low pH; poor peritoneal membrane biocompatibility; infusion pain; contains lactate	
Balance® (Fresenius‡)	7.0	Double	Lactate	Glucose	Low	Improved biocompatibility; preserved membrane defense; reduced risk of peritonitis?	Higher but not neutral pH; local and systemic glucose exposure; contains lactate	
BicaVera® (Fresenius‡)	7.4	Double	Bicarbonate	Glucose	Low	Improved biocompatibility; preserved membrane defense; improved correction of acidosis	Local and systemic glucose exposure	
Gambrosol® Trio (Fresenius‡)	6.5	Triple	Lactate	Glucose	Low	Improved biocompatibility; preserved membrane defense	Higher but not neutral pH; local and systemic glucose exposure; contains lactate	
*Deerfield, IL, USA. ‡Bad Homburg, Germany. Abbreviation: GDPs, glucose degradation products.								

Effects of Conventional Solutions






Effects of Conventional Solutions






Biocompatible Solutions






Effects of Biocompatible Solutions





Biocompatible Solutions in Children





PD Rx: Solution

Risk factors for loss of residual renal function in children treated with chronic peritoneal dialysis

Il-Soo Ha¹, Hui K. Yap², Reyner L. Munarriz³, Pedro H. Zambrano⁴, Joseph T. Flynn⁵, Ilmay Bilge⁶, Maria Szczepanska⁷, Wai-Ming Lai⁸, Zenaida L. Antonio⁹, Ashima Gulati¹⁰, Nakysa Hooman¹¹, Koen van Hoeck¹², Lina M.S. Higuita¹³, Enrico Verrina¹⁴, Günter Klaus¹⁵, Michel Fischbach¹⁶, Mohammed A. Riyami¹⁷, Emilja Sahpazova¹⁸, Anja Sander¹⁹, Bradley A. Warady²⁰ and Franz Schaefer²¹ for the International Pediatric Peritoneal Dialysis Network (IPPN) Registry²²


- Icodextrin associated with increased risk of developing oligoanuria HR 2.38 (1.33-4.2) and lower residual urine output (p=0.043)
- Biocompatible fluid associated with greater residual urine output (p=0.028)



PD Rx: Fill Volume

- Peritoneal membrane area is related to body size
- Use body surface area to calculate fill volume (as opposed to weight)
- Fill volume affects peritoneal membrane recruitment and diffusion capacity








PD Rx: Fill Volume

APD:

- Nocturnal fill volume:
 - >2 years: 1100-1400 mL/m²
 - $< 2 \text{ years: } 600-800 \text{ mL/m}^2$
- Daytime Fill volume:
 50% of nocturnal fill volume

CAPD:

- 600-800 mL/m² (day)
- 800-1000 mL/m² (night)





Measuring IPP

Intra-peritoneal pressure maximum 18 cm H₂O Normal 7-14 cm H₂O

- Empty bladder
- Patient placed completely flat
- Connection made to peritoneal system
- Any fluid in abdominal cavity is drained and defined volume of PD fluid is instilled
- PD line is fixed vertically
- Zero level of column (on graduated scale) is set at center of abdominal cavity, on the medial axillary line
- Connection of line to patient is opened
- Level of column of dialysis fluid in the PD line is read with a scale graduated in cm after height of column stabilizes



Fig. 1 The zero level of the column (on the graduated scale) is set at the centre of the abdominal cavity, i.e. medial axillary line


Mean IPP = $\underline{IPP \text{ insp} + IPP \text{ exp}}$

PD Rx: Excess Volume

Intra-peritoneal pressure maximum 18 cm H₂O Normal 7-14 cm H₂O

Excess volume:

- -Loss of UF
- -Pain
- -Risk of hernia
- -Risk of hydrothorax
- -Risk of breathing problems





PD Rx: Dwell Time

Short exchanges

- Clearance of small solutes (urea)
- Better ultrafiltration

Long exchanges


- Clearance of higher molecular weight (creatinine and phosphate)
- Less ultrafiltration

Dwell time should be determined by individual peritoneal membrane transport status



PD Rx: Dwell Time

Accelerated Peritoneal Examination APEX time indicates optimal dwell time for UF



PD Rx: # Exchanges

APD

- 5-10 exchanges overnight
- 9-12 hours
- Daytime dwell

CAPD

- 3-5 exchanges/day
- 4-5 hour dwell time, with longer overnight dwell



PD Rx cheat sheet

Automated PD

Solution:

1.5%, 2.5% or 4.25% dianeal

Fill volume (nocturnal):

< 2years old = 600-800 mL/m²

> 2 years old = 1100-1400 mL/m²

Last fill (daytime):

1/2 the nocturnal fill volume

#exchanges over #hours:

5-10 exchanges overnight over 9-12 hrs

Fill/Drain time: 15 minutes

Dwell time: 40-60 minutes

CAPD

Solution:

1.5%, 2.5% or 4.25% dianeal

Fill volume (daytime):

600-800 mL/m²

Long overnight dwell(nocturnal):

800-1000 mL/m²

exchanges:


3-5 exchanges/day with dwell time: 4 hours **AND**

1 nocturnal exchange with dwell time: ~9 hours



Peritoneal Equilibration Test (PET)

- Test of peritoneal membrane transport
- •4 hour dwell, 1,100 mL/m2 BSA, 2.5% Dextrose
- "Short" PET 2 hours






2 hours



PET: Transporter Type

Category of peritoneal transport	D/P urea ^a	D/P creatinine ^a	D/D0 glucose ^a
High	0.91-0.94	0.77-0.88	0.12-0.21
High average	0.82-0.90	0.64-0.76	0.22-0.32
Low average	0.74-0.81	0.51-0.63	0.33-0.42
Low	0.54-0.73	0.37-0.50	0.43-0.55

^aAt a 4 h dwell of an exchange performed with 1,100 ml/m² BSA of a 2.5% dextrose solution



Warady BA et al. JASN November 1996, 7(11):2385-2391 Pediatric Dialysis book, 3rd edition, 2021

PET: Transporter Type

Transporter Type	Characteristics	Prescription
High	-Highly permeable membrane -Rapid solute clearance -Loss of osmotic gradient quickly (poor UF) -Higher protein loss (lower albumin)	-Shorter dwell times -NIPD, or APD with icodextrin daytime fill
High Average	-Efficient membrane -Good solute clearance -Good UF	-Any dialysis regimen
Low Average	-Less efficient membrane -Slower solute clearance -Good UF	-Any dialysis regimen, but with fewer cycles
Low	-Low membrane permeability -Slow solute clearance -Very good UF -Lower protein loss (higher albumin)	-Larger fill volumes -Longer duration of dwell with less cycles -CAPD or CCPD



PD Rx: Modeled Approach

Kinetic Modeling Software Based Programs

- PD-Adequest 2.0 (Baxter)
 - Validated in children*
- Patient Online (Fresenius)



PD Rx: Adjustment

Inadequate Clearance

- Introduce daytime dwell
- Increase fill volume
- Lengthen dwell time
- Increase number of exchanges
- Increase solution tonicity

Inadequate Ultrafiltration

- Increase solution tonicity
- Icodextrin
- Shorten dwell time



PD Adequacy

Delivered dose of dialysis is "adequate":

- Optimal growth
- Blood pressure control
- Optimal nutritional status
- Avoidance of hypovolemia and sodium depletion
- Adequate psychomotor development



ISPD 2020 Dialysis Practice Recommendations

- Well-being of the person on dialysis is related to many different factors and not just removal of specific toxins
- High-Quality Goal-Directed PD
 - Maintain quality of life for PD patient
 - Minimize symptoms and treatment burden
 - Ensure high quality care



ISPD 2020 Dialysis Practice Recommendations

Shared decision making

Assessments:

- Patient reported outcome measures
- Fluid status
- Anemia
- Nutrition status
- Bone mineral management
- Removal of toxins

Preservation of residual kidney function




ISPD 2020 Dialysis Practice Recommendations

"PD prescription should be designed to meet medical, mental health, social and financial needs of the individual child and family"




PD Rx: Assessment






PD Rx: Assessment





PD Rx: Assessment





Adequacy: Measures of Clearance

- •Solute Clearance Measures:
 - Weekly Kt/V_{urea}
 - Weekly Creatinine Clearance
- •Guidelines and consensus statements historically have favored use of Kt/V_{urea} as the 'standard' measure to follow
 - No high-quality evidence regarding need or benefit associated with achievement of specific target*



Kt/V_{urea}

- "K" is representative of CLEARANCE of UREA
 - -Kd = clearance of dialysis delivered
 - -Kr = clearance of 'residual' renal function
- "t" is the time over which dialysis is delivered
 - -In PD calculations, "t" is normally considered 24 hours/day (calculation is based on full day of dialysate/urine output, then scaled to 1 week)
- "V"_{urea} is the volume of distribution for Urea in the patient, which is the patient's TBW



Total Kt/V_{urea} = dialysis + renal clearance

Weekly Peritoneal Dialysis Kt/V

24 Hr D/P urea x 24-hr drained volume x 7

V

Weekly Renal Kt/V

mL/min Urea clearance x 1440 min/day x 7 1000 mL x V

Daily Renal Urea Clearance

Volume of 24-hr urine in mL x Urine Urea Nitrogen Conc.

1440 min/day x BUN Concentration



Total Body Water Calculation

```
Males: TBW = 0.010
• (height • weight)<sup>0.68</sup>
- 0.37 • weight

Females: TBW = 0.14
• (height • weight)<sup>0.64</sup>
- 0.35 • weight
```



Table 17. Male Total Body Water (L) Nomograms

								Heig	ht (cm)								
	50	54	58	62	66	70	74	78	82	86	90	94	98	102	106	110	114
2	1.6	1.7	1.8	1.9	888888	2000	88888	8888	333333 33333 3333 3333 3333 3333 3333 3333							S	933333 3333
3	1.9	2.1	2.2	2.4		3000		833833	00000	88378	88888	88888	65555	33333	3333	83333	3333
4	2.2	2.4	2.6	2.8	3.0	2222		2000	2000	20000	(2000)						888888 8888888
5	2.4	2.7	2.9	3.1	3.3		SSSS	8888			XXXXX	88888 88888 8888 8888 8888 8888 8888 8888					2000
6	2.6	2.9	3.1	3.4	3.6	3.9	4.1				8888		33333				
7	2.8	3.1	3.4	3.6	3.9	4.2	4.4	4.7	4.9				3333	2000	20000	33333	
8	2.9	3.2	3.5	3.9	4.1	4.4	4.7	5.0	5.3	5.5	5.8		200		W. W.	3897	
9	2000			4.0	4.4	4.7	5.0	5.3	5.6	5.9	6.2	6.5	6.7		2000		
10	833333		833300	4.2	4.6	4.9	5.2	5.6	5.9	6.2	6.5	6.8	7.1	7.4	7.7		
11	******			4.4	4.8	5.1	5.5	5.8	6.2	6.5	6.8	7.1	7.5	7.8	8.1	8.4	8.7
12	888	*****	88888	4.5	4.9	5.3	5.7	6.0	6.4	6.8	7.1	7.5	7.8	8.1	8.5	8.8	9.1
13	33333		233333	2000	23333	20222	333333	6.3	6.6	7.0	7.4	7.8	8.1	8.5	8.8	9.2	9.5
14	30000	30000	(2000)			200000		6.5	6.9	7.3	7.7	8.0	8.4	8.8	9.2	9.5	9.9
15	88888							6.7	7.1	7.5	7.9	8.3	8.7	9.1	9.5	9.9	10.2
16	88000	33333 33333	20000	8000	8886		888	6.8	7.3	7.7	8.1	8.6	9.0	9.4	9.8	10.2	10.6
17						33333			33333	2332	8.4	8.8	9.2	9.7	10.1	10.5	10.9
18	2000		1000000						2000		8.6	9.0	9.5	9.9	10.4	10.8	11.2
19	88888	88888	22000	8888	XXXXX		33333			33333	8.8	9.3	9.7	10.2	10.6	11.1	11.5
20	000000	20000			00000	2000	0000			00000	9.0	9.4	9.9	10.4	10.9	11.3	11.8

Table 17 (cont'd). Male Total Body Water (L) Nomograms

										He	ight (cn	1)										
	106	110	114	118	122	126	130	134	138	142	146	150	154	158	162	166	170	174	178	182	186	190
20	10.9	11.3	11.8	12.3	12.7	13.2	13.6	14.0	14.5	14.9	15.3	15.7	(555)	5555	4555	50/50	9555	5550	5555	5/5/5/	555.55	M545
22	11.4	11.9	12.4	12.8	13.3	13.8	14.3	14.7	15.2	15.7	15.1	16.6	12/22	DOM:			12000	2000	2500	2000	2000	KO C
24	11.8	123	12.9	13.4	13.9	14.4	14.9	15.4	15.9	16.4	15.8	17.3	17.8	18.3	18.7	0.00	000	10000	COCK	4000	660	DO
26	12.2	128	13.3	13.9	14.4	15.0	15.5	16.0	16.5	17.0	17.5	18.0	18.5	19.0	19.5	100	95000	5655	93/5/5	555	5550	100
28	12.6	132	13.8	14.4	14.9	15.5	16.0	16.6	17.1	17.7	18.2	18.7	19.3	19.8	20.3	20.8	21.3	2002	12000	4000	25250	ROS:
30	13.0	136	14.2	14.8	15.4	16.0	16.6	17.1	17.7	18.3	18.8	19.4	19.9	20.5	21.0	21.6	22.1	0.00	CHOKOK	0.00	Q000	0.0
32	13.3	14.0	14,6	15.2	15.8	16.5	17.1	17.7	18.3	18.9	19.4	20.0	23.6	21.2	21.7	22.3	22.9	23.4	24/0		5656	100
34	13.8	14.3	15.0	15.6	16.3	16.9	17.5	182	18.8	19.4	20.0	20.6	212	21.8	22.4	23.0	23.6	24.2	24.7	200		525
36	13.9	14.6	15.3	16.0	16.7	17.3	18.0	18.7	19.3	19.9	20.6	21.2	218	22.4	23.1	23.7	24.3	24.9	25.5	26.1	26.6	A 9
38	14.2	14.9	15.7	16.4	17.1	17.8	18.4	19.1	19.8	20.4	21.1	21.9	22.4	23.0	23.7	24.3	24.9	25.6	26.2	26.8	27.4	1000
40	CACALIS	A00040	18.0	16.7	17.4	18.1	18.8	19.5	20.2	20.9	21.6	22.3	23.0	23.6	24.3	24.9	25.6	28.2	26.9	27.5	28.1	28.
42	98555	5955	18.3	17.0	17.8	18.5	19.2	20.0	20.7	21.4	22.1	22.8	23.5	24.2	24.9	25.5	26.2	23.9	27.5	28.2	28.8	29
44	200000	2000	18.6	17.3	18.1	18.9	19.8	20.4	21.1	21.8	22.6	23.3	24.0	24.7	25.4	28.1	26.8	27.5	28.2	28.8	29.5	30
46	OC C	1000	16.8	17.6	18.4	19.2	20.0	20.8	21.5	22.3	23.0	23.8	24.5	25.2	26.0	28.7	27.4	28.1	28.8	29.5	30.2	30
48	1000	5/5/5	17.1	17.9	18.7	19.5	20.3	21.1	21.9	22.7	23.5	24.2	25.0	25.7	26.5	27.2	27.9	28.7	29.4	30.1	30.8	31.
50	20000	222	17.3	18.2	19.0	19.8	20.7	21.5	22.3	23.1	23.9	24.7	25.4	26.2	27.0	27.7	28.5	29.2	30.0	30.7	31.5	32
52	CACACA	XXXX	0.000	8000	000	20.1	21.0	21.8	22.5	23.5	24.3	25.1	25.9	26.7	27.5	28.2	29.0	29.8	30.6	31.3	32.1	32
54	5500	000	0000	13:35	9556	20.4	21.3	22.1	23.0	23.8	24.7	25.5	25.3	27.1	27.9	28.7	29.5	30.3	31.1	31.9	32.7	33
56	0.000	12000	2000	12000	1000	20.7	21.6	22.5	23.3	24.2	25.0	25.9	29.7	27.6	28.4	29.2	30.0	30.8	31.7	32.4	33.2	34
58	5555	1956	\$555.4	35500	0000	20.9	21.8	22.8	23.7	24.5	25.4	26.3	27.1	28.0	28.8	29.7	30.5	31.4	32.2	33.0	33.8	34
60	20:00	999	2000	999	3000	21.2	22.1	23.1	24.0	24.9	25.8	26.7	27.5	29.4	29.3	30.1	31.0	31.8	32.7	33.5	34.4	35
62	CHOICE	SCHOOL ST	6000	9000	CROSS	21.4	22.4	23.3	24.3	25.2	26.1	27.0	27.9	28.8	29.7	30.6	31.5	32.3	33.2	34.0	34,9	35
64	55656	3545	15/5/5/5	Carlo V	50,000	21.7	22.6	23.6	24.5	25.5	28.4	27.4	29.3	29.2	30.1	31.0	31.9	32.8	33.7	34.5	35.4	36
66	1 M. M. W.	00 at 20	S 600	200	5000	595900	2000	195520	24.8	25.8	28.8	27.7	28.6	29.6	30.5	31.4	32.3	33.2	34.1	35.0	35.9	36
68	\$5555	8358	6555	855	5555	355	505030	55205	25.1	26.1	27.1	26.0	29.0	30.0	30.9	31.8	32.8	33.7	34.6	35.6	36.4	37
70	2000	0.50	00000	0.00	2000	000	5000	1000	25.4	26.4	27.4	28.4	29.3	30.3	31.3	32.2	33.2	34.1	35.1	38.0	36.9	37
72	CKKX	4.4	4000	ALC: N	0.000	355	6000	0.000	25.5	26.6	27.7	28.7	29.7	30.7	31.6	32.6	33.6	34.5	35.5	35.4	37.4	35
74	S. N. W. W.	16, 2, 2	1000	N. H. S.	W W AL A	10, 200	A 35 A	CALALA	25.9	26.8	27.9	29.0	30.0	31.0	32.0	33.0	34.0	34.9	35.9	35.9	37.8	35
76	833	203	9000	1300	9300	8 N S 8	N H A	W. S. S. S.	26.1	27.2	28.2	29.3	30.3	31.3	323	33.3	34.4	35.3	36.3	37.3	38.3	39
78	600	0.00	4500	1000	0.00	100	K N K	1000	26.3	27.4	28.5	29.5	30.6	31.6	32.7	33.7	34.7	35.7	36.7	37.7	38.7	39.
80	175,00	15 N. P.	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	15,50	A 18 4	300	10 mg	100 M	26.5	27.6	28.7	29.8	30.9	31.9	33.0	34.1	35.1	36.1	37.1	38.2	39.2	40.

								Heig	ht (cm)								
	50	54	58	62	66	70	74	78	82	86	90	94	98	102	106	110	11
2	2.0	2.1	2.2	2.4	88888	2000		25200	33333	88888							888
3	2.4	2.6	2.8	2.9	9333	20000				000000	9333	33333	*****	333333	33333	883	800
4	2.8	3.0	3.2	3.4	3.6	33353	2333	33333	\$35333	233333	333333	330000	33333	\$333330	33333	2000	833
5	3.1	3.3	3.5	3.8	4.0			20000	2000	388833	80000				88888	88888	333
6	3.3	3.6	3.8	4.1	4.3	4.6	4.8	68600	50000		98938						
7	3.5	3.8	4.1	4.4	4.8	4.9	5.2	5.5	5.7		00000				******	20000	8300
8	3.7	4.0	4.3	4.6	4.9	5.2	5.5	5.8	6.1	6.4	6.6						888
9	0.9900			4.9	5.2	5.5	5.8	6.1	6.4	6.7	7.0	7.3	7.6	\$33300	******		5335
10				5.1	5.4	5.8	6.1	6.4	6.8	7.1	7.4	7.7	8.0	8.3	8.6	20000	
11	200000	200000	833333	5.3	5.6	6.0	6.4	6.7	7.1	7.4	7.7	8.1	8.4	8.7	9.0	9.3	9.
12	33333	2000	2333	5.4	5.8	6.2	6.6	7.0	7.3	7.7	8.0	8.4	8.7	9.1	9.4	9.7	10.
13			8888	(C)				7.2	7.6	8.0	8.3	8.7	9.1	9.4	9.8	10.1	10
14	8888	88888	200000	2000	1888			7.4	7.8	8.2	8.6	9.0	9.4	9.7	10.1	10.5	10
15			8888	SSS 55			8888	7.6	8.0	8.5	8.9	9.3	9.7	10.0	10.4	10.8	11.
16		2000	000000	300 C	33333	1 00000		7.8	8.3	8.7	9.1	9.5	9.9	10.3	10.7	11.1	11.
17		2000		2000	35500		100000		10000		9.3	9.8	10.2	10.6	11.0	11.4	11.
18	S7556	3000	8898	388	00000	\$3434	3223		200	92833	9.6	10.0	10.5	10.9	11.3	11.7	12
19	20,000	33333	1000 C	3200	2000	23333	1000000	1000	88888	2000	9.8	10.2	10.7	11.1	11.6	12.0	12
20	866	22002	20000	22.55	33353	10000	100000	33333	55000	200000	10.0	10.4	10.9	11.4	11.8	12.3	12

	4000				diam'r.		Height (cm)															
	106	110	114	118	122	126	130	134	138	142	146	150	154	158	162	166	170	174	178	182	186	190
20	11.8	12.3	12.7	13.2	13.6	14.0	14.5	14.9	15.3	15.7	16.1	16.5		10 TO	000000	1000		553500	SERVE	10000	E PAR	12000
22	12.3	12.8	13.3	13.7	14.2	14.7	15.1	15.6	16.0	16.4	16.9	17.3	65.00	10000	533(H.5)	1000	15000	38999	2000	9000	N5969	7523
24	12.8	13.3	13.8	14.3	14.8	15.2	15.7	16.2	16.7	17.1	17.6	18.0	18.5	18.9	19.4	100000	SERVE	THE REAL PROPERTY.	F2000	5.000	00000	2000
26	13.2	13.7	14.2	14.8	15.3	15.8	16.3	16.8	17.3	17.8	18.3	18.7	19.2	19.7	20.1	Service.		200	HER THE SE	ROSE CO	0.005	10000
28	13.6	14.1	14.7	15.2	15.8	16.3	16.8	17.3	17.9	18.4	18.9	19.4	19.9	20.4	20.9	21.3	21.8	92200	50000	6000 P	5/99/5	10000
30	13.9	14.5	15.1	15.7	16.2	16.8	17.3	17.9	18.4	18.9	19.5	20.0	20.5	21.0	21.5	22.0	22.5	RIPS CO.	10000	200 A	2000	Total !
32	14.3	14.9	15.5	16.1	16.6	17.2	17.8	18.4	18.9	19.5	20.0	20.6	21.1	21.7	22.2	22.7	23.2	23.7	24.3	35,265	0.00	10000
34	14.6	15.2	15.8	16.4	17.0	17.7	18.2	18.8	19.4	20.0	20.6	21.1	21.7	22.3	22.8	23.4	23.9	24.4	25.0	tickets:	NG (1999)	9325
36	14.8	15.5	16.2	16.8	17.4	18.1	18.7	19.3	19.9	20.5	21.1	21.7	22.3	22.8	23.4	24.0	24.5	25.1	25.6	26.2	26.7	36363
38	15.1	15.8	16.5	17.1	17.8	18.4	19.1	19.7	20.3	21.0	21.6	22.2	22.8	23.4	24.0	24.6	25.1	25.7	26.3	26.9	27.4	10000
40	527,90	25000	16.8	17.4	18.1	18.8	19.5	20.1	20.7	21.4	22.0	22.7	23.3	23.9	24.5	25.1	25.7	26.3	26.9	27.5	28.1	28.6
42	515660	020050	17.0	17.7	18.4	19.1	19.8	20.5	21.1	21.8	22.5	23.1	23.8	24.4	25.0	25.7	26.3	26.9	27.5	28.1	28.7	29.3
44	HE0330	275765	17.3	18.0	18.7	19.5	20.2	20.9	21.5	22.2	22.9	23.6	24.2	24.9	25.5	26.2	26.8	27.4	28.1	28.7	29.3	29.9
46	655365	22/6/37	17.5	18.3	19.0	19.8	20.5	21.2	21.9	22.6	23.3	24.0	24.7	25.3	26.0	26.7	27.3	28.0	28.6	29.3	29.9	30.5
48	152539	32333	17.8	18.5	19.3	20.0	20.8	21.5	22.3	23.0	23.7	24.4	25.1	25.8	26.5	27.2	27.8	28.5	29.2	29.8	30.5	31.1
50	150000	8-203	18.0	18.8	19.6	20.3	21.1	21.8	22.6	23.3	24.1	24.8	25.5	26.2	26.9	27.6	28.3	29.0	29.7	30.4	31.0	31.7
52	3650000	extinat.	POPER	525000	USS 1878	20.6	21.4	22.1	22.9	23.7	24.4	25.2	25.9	26.6	27.4	28.1	28.8	29.5	30.2	30.9	31.6	32.2
54	1502-045	23320	9959	S0235	10230	20.8	21.6	22.4	23.2	24.0	24.8	25.5	26.3	27.0	27.8	28.5	29.2	29.9	30.7	31.4	32.1	32.8
56	1550150	0.0360	563-05	25000	SAPA	21.1	21.9	22.7	23.5	24.3	25.1	25.9	26.6	27.4	28.2	28.9	29.7	30.4	31.1	31.9	32.6	33.3
58	000000	808053	200	SECTION .	100000	21.3	22.1	23.0	23.8	24.6	25.4	26.2	27.0	27.8	28.5	29.3	30.1	30.8	31.6	32.3	33.1	33.8
60	1000000	1000	10.00	SCHOOL SECTION	122/653	21.5	22.4	23.2	24.1	24.9	25.7	26.5	27.3	28.1	28.9	29.7	30.5	31.3	32.0	32.8	33.5	34.3
62	804.355	2000	THE SECOND	0.010.000	94736	21.7	22.6	23.4	24.3	25.2	26.0	26.8	27.7	28.5	29.3	30.1	30.9	31.7	32.4	33.2	34.0	34.8
64	503000	555000	5555055	204 220	0503/5	21.9	22.8	23.7	24.6	25.4	26.3	27.1	28.0	28.8	29.6	30.4	31.3	32.1	32.9	33.6	34.4	35.2
66	0.000	20706	美艺品的图	8055760	SEC.	See See See	550000	CONTRACTOR OF THE PERSON NAMED IN	24.8	25.7	26.5	27.4	28.3	29.1	30.0	30.8	31.6	32.4	33.2	34.1	34.9	35.7
68	105/00/02	122360	10520530	Property.	63350	M100000	20493	923564	25.0	25.9	26.8	27.7	28.6	29.4	30.3	31.1	32.0	32.8	33.6	34.5	35.3	36.1
70	950,500	2000000	C1945-0	200000000	25/226	479/39/5	120000	PRODUCT NA	25.2	26.1	27.0	27.9	28.8	29.7	30.6	31.5	32.3	33.2	34.0	34.9	35.7	36.5
72	SUPPLIES.	3000.000	NEWS AND ADDRESS OF	Contractor of	892.53	505000	5 3 2 3	Market Co.	25.4	26.4	27.3	28.2	29.1	30.0	30.9	31.8	32.7	33.5	34.4	35.2	36.1	36.9
74	Sales States	THE REAL PROPERTY.	500000	SECOND .	48,630	100000	Signer or	TSINGS.	25.6	26.6	27.5	28.4	29.4	30.3	31.2	32.1	33.0	33.9	34.7	35.6	36.5	37.3
76	BECKE ST	(To 100 and 1	STATE OF THE PARTY OF	No.	Shorter S	055550	007000	THE REAL PROPERTY.	25.8	26.8	27.7	28.7	29.6	30.6	31.5	32.4	33.3	34.2	35.1	36.0	36.8	37.7
78	100 mm	1000000	THE REAL PROPERTY.	100000	0.00	Sept.	9 PKS)	25 25	26.0	27.0	27.9	28.9	29.9	30.8	31.7	32.7	33.6	34.5	35.4	36.3	37.2	38.1
80	2000 CO	TO STORE AND	THE REAL PROPERTY.	No. of Concession,	1000000	100000	Region to	-	26.2	27.2	28.1	29.1	30.1	31.1	32.0	33.0	33.9	34.8	35.7	36.7	37.6	38.5

Solute Clearance

- PD prescription should be adjusted with goal of achieving a normal serum phosphate level
- •Total minimum weekly Kt/V_{urea}=1.7
 - If less than 1.7 and otherwise doing well, should not have PD prescription increased for sole purpose of meeting target




Residual Kidney Function

- Should be measured when UOP > 100 mL/day
- Defined as urine Kt/V_{urea} > 0.1/week
- 24 hour urine collection for urine volume and solute clearance determinations should be obtained at a minimum of every 3 months



Residual Kidney Function



NKF KDOQI Guidelines 2006

Prescribing peritoneal dialvsis for high-quality care in children. Kidney Int. 2015 Sep; 88(3): 605–613. -340.



Management

- The pediatric patient's clinical status should be reviewed at least monthly, and delivery of prescribed solute clearance should render the patient free of signs and symptoms of uremia
- Measure Kt/V one month after starting dialysis, when clinically needed and at least every 6 months
- PD effluent UF should be reviewed every month



Summary

- PD prescription must be individualized and optimized, and continually re-assessed
- While recommended minimal "delivered" dose of solute clearance should be a Kt/V_{urea} 1.7/week, adequacy is also determined by clinical outcomes of the patient
 - BP control, fluid management, growth, nutrition, bone disease, development, and quality of life

Useful Resources

- Optimal Care of the Infant, Child and Adolescent on Dialysis: 2014 Update. Am J Kidney Dis 2014; 64(1):128-142
- Care of the Pediatric Patient on Chronic Dialysis. Adv Chronic Kidney Dis 2017; 24(6): 388-397
- Pediatric Dialysis, 3rd Edition. Warady, Schaefer, Alexander.
 - Chapter 13 Technical Aspects of Prescription of Peritoneal Dialysis in Children, p 193-228
- Handbook of Dialysis, 5th Edition. Daugirdas, Blake and Ing.
 - Chapter 25 Adequacy of Peritoneal Dialysis p464-482
 - Chapter 26 Volume Status and Fluid Overload in Peritoneal Dialysis p483-489
 - Chapter 37 Dialysis in Infants and Childrren p693-712
- KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for 2006 Updates. Hemodialysis Adequacy, Peritoneal Dialysis Adequacy and Vascular Access. Am J Kidney Dis 2006; 28(suppl 1): S1
- Prescribing peritoneal dialysis for high-quality care in children. *Perit Dial Int 2020;* 40(3)333-340.
- International Society for Peritoneal Dialysis practice recommendations: Prescribing high-quality goal-directed peritoneal dialysis. *Perit Dial Int 2020; 40(3)244-253.*

Peritoneal Dialysis Simulator www.Openpediatrics.org Harvard University

OPEN PEDIATRICS". OPEN PEDIATRICS . Dialysis Prescription Fill Volume Examine and evaluate your patient by Initial fill volumes are typically 5-10 completing the actions below: mL/kg, with gradual increases up to 20 to 25 mL/kg in smaller infants, and 30-45 1.5% 1. Assess the Patient mL/kg in older children. In this simulator, 2 Monitor Vital Signs start your fill volumes at 5 mL/kg, and increase your fill volumes to promote 3. Check Fluid Balance increased clearance as needed. 4. Check Effluent The volume of each fill limits the amount 5. Check Lab Results of clearance that one can achieve, as molecules can only move down a concentration gradient. Thus, the volum Select a Condition... of dialysate instilled in a 24-hour period is 1 Hour n clearance achieved, equilibrium between blood and dialysate, Results - Day 1 and thus the clearance may be less than the volume of dialysate PD Input PD Output 220 mL Steps To Advance PD Balance -20 mL Patient Info Effluent 1. Select 5 mL/kg from the Fill Volume NAME: Ryan WEIGHT: 2.7 kg LOCATION-NICU OPEN PEDIATRICS . **Your Patient Chart** Congratulations! Your final score is 90%. Helen, a previously healthy 7-year-old girl, presented to the emergency department with several days of high fevers, pallor and malaise. On presentation, she was tachycardic and hypotensive, and had a prolonged capillary refill time. ✓ Task 1: Initial Setup m score 100% Helen was admitted to the hospital where she was resuscitated with multiple boluses of crystalloid fluid. She also received a blood transfusion. Following Task 2: Inadequate Drain Bag Height resuscitation, she became edematous but required vasopressors for low blood Task 3: Poor Ultrafiltration pressure, which are now weaning off In the last 24 hours, she has only made 5 mL of urine. Diuretics were administered Task 4: Dehydration without any improvement in urine output. A peritoneal dialysis catheter was Task 5: Hyponatremia 58% inserted at the bedside in aseptic manner. A KUB shows the catheter in good Task 6: Hypokalemia 100% PATIENT NAME: Helen PATIENT AGE: 7 years Score 95% or better to DATIENT WEIGHT, 23 km


Screenshots of the various components of the peritoneal dialysis simulator. (A) The knowledge quide. (B) The tactics. (C) The case studies. (D) Learner-controlled feedback

???Questions???

Thank you!



Adapted APD






PET: Transporter Type


Category of peritoneal transport	D/P urea ^a	D/P creatinine ^a	D/D0 glucose ^a
High	0.91-0.94	0.77-0.88	0.12-0.21
High average	0.82-0.90	0.64-0.76	0.22-0.32
Low average	0.74-0.81	0.51-0.63	0.33-0.42
Low	0.54-0.73	0.37-0.50	0.43-0.55

^aAt a 4 h dwell of an exchange performed with 1,100 ml/m² BSA of a 2.5% dextrose solution



B A Warady, S R Alexander, S Hossli, E Vonesh, D Geary, S Watkins, I B Salusky and E C Kohaut JASN November 1996, 7 (11) 2385-2391;

Effects of Conventional Solutions





Ultrafiltration Adequacy: Euvolemia

Causes of Fluid Overload

- Inappropriate solution selection
- Inappropriate prescription for membrane transport status
- Non-adherence to PD or diet
- Peritoneal membrane dysfunction
- Loss of residual kidney function
- Poor blood glucose control

